An Introduction to Psoriatic Arthritis
Psoriatic arthritis is a chronic, progressive, inflammatory form of arthritis, which develops in up to 30% of people with psoriasis and is associated with increased risk of systemic inflammatory disease. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, disease-modifying antirheumatic drugs (DMARDs) and biologic therapies, including inhibitors of tumour necrosis factor (TNF) α, interleukin (IL)-12, IL-23 and IL-17. Recently approved therapies include the Janus kinase (JAK) inhibitors, and other promising agents in development include tyrosine kinase inhibitors. Future challenges include personalised medicine, earlier diagnosis and achieving a low-level of disease activity.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Psoriatic Arthritis Content
Maarten Boers, EULAR 2021: Findings from the ULTIMATE Clinical Trial
It was great to talk with Prof. Maarten Boers (VU University Medical Center, Amsterdam, The Netherlands) to discuss the responsiveness and high discriminative validity of GLOESS and clinical outcomes of synovitis in PsA patients treated with secukinumab from the ULTIMATE Trial. The abstract ‘Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic Arthritis Treated with […]
Xenofon Baraliakos, EULAR 2021: Findings from the MAXIMISE Study
It was a pleasure to meet with Prof. Xenofon Baraliakos (Ruhr-University Bochum, Herne, Germany) to talk around his presentation on ‘Secukinumab in patients with psoriatic arthritis and axial manifestations: Predictors of response from the double-blind, randomised, phase 3b MAXIMISE trial.‘ (POS0930), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021. Questions […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Maria-Antonietta D’Agostino, EULAR 2021: The OMERACT-US Enthesitis Score in Psoriatic Arthritis
It was a pleasure to meet with Prof. Maria-Antonietta D’Agostino (Versailles-Saint-Quentin University and University Hospital Ambroise Paré, Boulogne-Billancourt, France) to discuss her study investigating the responsiveness of the global OMERACT-US enthesitis score in the ULTIMATE clinical study. The abstract ‘Towards development of an ultrasound enthesitis score in psoriatic arthritis: 24-week results from the phase III […]
Christopher Ritchlin, ACR 2020 – Results from the DISCOVER-1 Phase 3 Trial
We were delighted to speak to Christopher Ritchlin (University of Rochester, Henrietta, NY, USA) about the one year results from the DISCOVER-1 Phase 3 trial of guselkumab in active psoriatic arthritis (Clinical Trial Identification: NCT03162796). The abstract ‘Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of […]
Deepak Jadon, ACR 2020 – Psoriatic Arthritis Research Highlights 2020
It was a pleasure to speak to Deepak Jadon (Cambridge University Hospitals, Cambridge, UK) about his research highlights from this year in the field of psoriatic arthritis (PsA) and his highlights from the annual ACR Convergence meeting. Questions What have been the most notable research articles published in PsA this year? (0:05) What were the […]
Laure Gossec, ACR 2020 – Results from the BE ACTIVE Study
We were delighted to speak to Laure Gossec (Sorbonne Université and Pitié-Salpétrière Hospital, Paris, France) about the 48-week results of the BE ACTIVE phase 2b study of bimekizumab in psoriatic arthritis (Clinical Trial Identifier: NCT02969525). The abstract ‘Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported […]
Laura Coates, ACR 2020 – Results from the FUTURE 5 Study
We caught up with Laura Coates (University of Oxford, Oxford, UK) to discuss the results from FUTURE 5, the phase 3 study of secukinumab in patients with psoriatic arthritis (Clinical Trial Identifier: NCT02404350). The abstract ‘Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!